SEARCH

SEARCH BY CITATION

References

  • 1
    Fesler P, du Cailar G, Ribstein J, et al. Heterogeneity of cardiorenal characteristics in normotensive subjects. Hypertension. 2004;43:219223.
  • 2
    Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:15711576.
  • 3
    Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:1318.
  • 4
    Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:19031913.
  • 5
    Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:12911297.
  • 6
    Volpe M, Ruilope LM, McInnes GT, et al. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens. 2005;19:331339.
  • 7
    Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3:283291, 318.
  • 8
    Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens. 2005;18:287294.
  • 9
    Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5:4150.
  • 10
    The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:24132446.
  • 11
    Marbury T, Wang A, Jones. M. Efficacy of olmesartan medoxomil, losartan potassium, and valsartan in black patients. Am J Hypertens. 2005;18:A6869.
  • 12
    Chrysant S, Wang A, Jones M. Efficacy of olmesartan medoxomil, losartan potassium, and valsartan in a nonblack patient cohort. Am J Hypertens. 2005;18:A5354.
  • 13
    Neutel J, Lee Y, Walker F. Efficacy of olmesartan medoxomil, losartan potassium, and valsartan in diabetic patients. Am J Hypertens. 2005;18:A69.
  • 14
    Giles T, Oparil S, Silfani T, et al. Comparison of ascending doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. Am J Hypertens. 2005;18:A59A60.
  • 15
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:20222031.
  • 16
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:20492051.
  • 17
    2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:10111053.
  • 18
    Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 19
    JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(suppl 5):v152.
  • 20
    Weber M, Basile J, Izzo J Jr, et al. Roundtable discussion: blood pressure goal attainment: meeting the challenge of the JNC 7's blood pressure goals and the role of renin-angiotensin- aldosterone system blockade. J Clin Hypertens (Greenwich). 2004;6:699705.